Written and maintained by CASRAI Editorial Board
Last updated
Off-label drug use means a licensed prescriber gives a patient an FDA-approved drug for a purpose the FDA has not approved it for — a different diagnosis, dose, patient population (such as children when a drug is only approved for adults), or route of administration than what appears on the drug’s official label. The drug itself has cleared FDA review and is legally on the market; what has not been reviewed is this particular use of it.
This is a routine, legal, and extremely common part of medical practice — not a loophole or a sign that something has gone wrong. Estimates vary by specialty, but off-label prescribing is especially widespread in oncology, pediatrics, and psychiatry, where the pace of clinical evidence often outruns the pace of formal FDA labeling updates.
Why off-label prescribing is legal
The FDA regulates which uses a drug’s manufacturer may claim, test for approval, and promote — it does not regulate how an individual, licensed physician exercises clinical judgment with an already-approved drug. This is often summarized as the practice-of-medicine principle: once a drug is approved and on the market, FDA approval controls what a manufacturer can put on the label and advertise, not what a physician can prescribe based on the medical literature, clinical guidelines, and the needs of the specific patient in front of them.
The asymmetry that trips people up is exactly here: a physician prescribing off-label is on solid legal ground; a manufacturer promoting a drug for an unapproved use is not. Marketing a drug for a use FDA has not approved can render it misbranded under the Federal Food, Drug, and Cosmetic Act, and FDA and the Department of Justice have brought substantial enforcement actions against manufacturers over exactly this line — off-label promotion, not off-label prescribing, is what regulators pursue.
How it differs from investigational (IND) drug use
Off-label use is easy to confuse with investigational use, but they sit on opposite sides of FDA approval. Off-label use involves a drug that is already FDA-approved — only this particular use of it falls outside the approved label. Investigational use involves a drug that is not yet approved for any use and is being studied under an FDA-authorized Investigational New Drug (IND) application, typically within a formal clinical trial designed to generate the safety and efficacy data FDA needs to eventually approve it.
A related pathway worth distinguishing too: expanded access (“compassionate use”) lets a patient receive a drug that has not yet been approved, outside a clinical trial, when no satisfactory approved alternative exists. Off-label use never requires this kind of special authorization, because the underlying drug is already approved — the physician is simply applying it beyond its labeled scope, which the FDA’s approval framework was never designed to constrain in the first place.
| Concept | Is the drug FDA-approved? | Special FDA authorization needed? |
|---|---|---|
| Off-label use | Yes, for a different use | No |
| Investigational (IND) use | No, not for any use | Yes — an IND |
| Expanded access / compassionate use | Usually no | Yes — expanded access authorization |
Who this applies to, and where it shows up
Off-label use is a physician-and-patient-level clinical decision, made case by case — it is not a status a drug carries in general, and it is not something a hospital or research institution formally “approves” the way it approves a trial protocol. That said, several groups working around clinical research routinely have to reason about it:
- Institutional Review Boards and ethics reviewers encounter off-label use when a trial protocol specifies a marketed drug as a background therapy, comparator, or rescue medication used outside its approved label — informed consent language needs to make that clear to participants.
- Regulatory affairs and medical affairs staff are the ones who have to keep promotional and medical-communications material inside the manufacturer-promotion line described above, since that is the boundary FDA actually enforces.
- Research billing and compliance staff deal with a distinct, practical question: whether a payer will reimburse an off-label use. Coverage is not automatic; some payers, including Medicare in certain circumstances (most established in oncology), will cover an off-label use if it is supported by recognized drug compendia or sufficient published evidence, but this is a payer-and-context-specific determination, not a blanket rule.
- Investigators and research pharmacy staff need to distinguish off-label drug administration that is simply part of standard clinical care for a patient from off-label use written into a research protocol, which typically carries its own consent, monitoring, and reporting obligations tied to the study itself rather than to routine practice.
Frequently asked questions
Is off-label drug use legal?
Yes. FDA does not restrict how a licensed physician may prescribe an already-approved drug in the practice of medicine. What is restricted is a manufacturer promoting or marketing the drug for a use FDA has not approved.
Is off-label use the same as experimental or investigational use?
No. Off-label use involves a drug that is already FDA-approved, just not for this particular use. Investigational use involves a drug that has not been approved for any use yet and is being studied under an FDA-authorized IND application.
Can a drug company get in trouble for off-label use?
A manufacturer cannot be penalized for a physician’s independent off-label prescribing decision, but it can face significant FDA and Department of Justice enforcement if it promotes, markets, or trains its sales force to encourage an unapproved use — that promotional activity is what triggers misbranding liability, not the prescribing itself.
Will insurance pay for an off-label prescription?
Sometimes. Coverage depends on the payer and the specific use; some off-label uses, particularly in oncology, are covered when supported by recognized drug compendia or strong published evidence, while others are denied as not medically necessary or investigational. There is no single rule that applies across all payers.
Does off-label use require special FDA approval?
No. Because the underlying drug is already FDA-approved, an individual off-label prescription does not require a separate FDA authorization the way investigational use (via an IND) or expanded access does.
